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Purpose. To compare infection with the tapeworm, Hymenolepis diminuta, with steroid (dexamethasone) administration in the
inhibition of dinitrobenzene sulfonic acid- (DNBS-) induced colitis in mice. Procedures. Mice were treated with DNBS ± infected
with H. diminuta or treated with daily dexamethasone (2mg/Kg, ip.) and were assessed 72 hours post-DNBS by the calculation
of disease activity and histological damage scores, and spleen cell cytokine production. Results. H. diminuta-infected mice showed
increased IL-4 and IL-10 production by spleen cells compared to other groups and were protected from DNBS-induced colitis. In
contrast, there was little beneﬁt of dexamethasone in the treatment of colitis. Collagen deposition in the colon was not diﬀerent
between the groups. Conclusions. H. diminuta was superior to dexamethasone in the prevention of DNBS-induced colitis and did
not result in additional side eﬀects (i.e., collagen deposition). Comparisons with current therapeutics and long-term followup to
studies are essential if “helminth therapy” is to become a viable treatment for speciﬁc inﬂammatory diseases in the gut or other
tissues.
1.Introduction
During the last three decades there have been dramatic
increases in autoimmune and inﬂammatory diseases, such
as allergy/atopy, diabetes, and inﬂammatory bowel disease
(IBD) that cannot be explained solely on the basis of
genetics [1]. In the search for environmental triggers for
these conditions, the hygiene hypothesis has arisen that
suggests that reduced exposure to infectious agents (via
increases in hygiene, sterile drinking water, and use of
antibiotics) may result in the generation of greater numbers
of autoreactive immune cells in humans, and hence the
emergence of autoimmune and idiopathic inﬂammatory dis-
ease [2]. Compatible with this postulate is the geographical
divergence in the occurrence of diseases such as IBD and
areas of pandemic helminth infection [3]. Epidemiological
data must be viewed cautiously when used in support of
causation rather than association. They do nevertheless raise
thequestion:couldinfectionwithparasitichelminthsprotect
against other concomitant disease?
Representatives of all classes of helminth parasite have
been shown to modulate immunity in their hosts, both qual-
itatively and quantitatively [4–6]. Moreover, infection with
helminth parasites evokes stereotypic immune responses in
humans and mice that are dominated by T helper 2 (TH2)
cytokines. Thus as putative modiﬁers of disease, the release
of immunomodulatory or immunosuppressive molecules
from helminths would be expected to impact on concurrent
disorders in the host, and the stimulation of TH2 events
has the potential to antagonize or inhibit diseases in which
the immunopathology is driven by TH1 reactions. We have
shown that infection with the rat tapeworm, Hymenolepis
diminuta, protects mice from the colitic eﬀects of direct
instillation of dinitrobenzene sulfonic acid (DNBS) into the
lumen of the colon [7]. A substantial amount of data has
amassed showing that a variety of species of helminths2 Journal of Biomedicine and Biotechnology
(e.g., H. diminuta, Trichinella spiralis, Heligosomoides poly-
gyrus, Schistosoma mansoni) reduce the severity of disease in
rodent models of IBD, airways inﬂammation, and multiple
sclerosis [8]. In the context of developing new treatments,
two major possibilities arise from these proof-of-concept
studies: (1) use of the immunological knowledge gleaned
from these models to deﬁne new targets for pharmacological
intervention; and (2) the prescription of a “therapeutic
helminth(s)” to deﬁnedgroups ofpatients thatarerefractory
to other therapies. The latter is a provocative idea and,
despitethespectreofiatrogenicdisease[9],studieshavebeen
presented in which nematodes, namely, Trichuris suis and
Necator americanus, have been used to treat IBD and as a
putative forerunner to use in asthma, respectively [10, 11].
As the concept of a “therapeutic helminth” progresses
it is important that appropriate comparisons with current
therapies and potential side eﬀects be rigorously assessed.
Using the H. diminuta-DNBS murine model system, the
current study addresses two questions. Will H. diminuta
be as eﬀective as steroids in the treatment of DNBS-
induced colitis? And, is helminth therapy in this acute model
associated with increased collagen deposition that could
result in ﬁbrosis and stricture formation? Using this acute
and spontaneously resolving chemical model of colitis we
present data showing that infection with H. diminuta is
superior to daily steroid therapy and that infected mice,
while receiving substantial anti-inﬂammatory beneﬁt from
infection, displayed no greater collagen deposition in their
colons than mice receiving DNBS only.
2.MaterialsandMethods
2.1. Murine Model System. Male 6–8 Balb/c mice (Charles
River Animal Supplies, Montreal, QB, Canada) were housed
in ﬁlter-topped cages with free access to water and rodent
chow and on a 12 hour : 12 hour light : dark cycle [7].
Colitis was induced in anesthetized mice via intrarectal (ir.)
instillationofDNBS(3.0or2.5mgin100μLof50%ethanol)
delivered 3cm into the colon via a polyethylene catheter
[7]. Time-matched control mice received 50% ethanol only.
A third group of mice were infected with ﬁve H. diminuta
cysticercoids via oral gavage in 100μL 0.9% NaCl, eight days
prior to receiving DNBS [12]. The ﬁnal group of animals
was treated with the glucocorticoid, dexamethasone (DEX;
Sigma Chemical Co., St. Luois, MO) and DNBS (n = 3–
8 mice/group). Based on previous reports in which DEX
was used to suppress inﬂammatory disease [13–15]m i c e
was treated with either 1mg or 2mg/Kg administered by
intraperitoneal (ip.) injection on three consecutive days
beginning one hour after DNBS treatment (the eﬀects of
1 and 2mg/Kg DEX were not signiﬁcantly diﬀerent and so
the data have been combined and are considered as a single
group in the results section). All experiments adhered to the
Canadian guidelines for animal welfare and complied with
the speciﬁc ethical regulations of the University of Calgary.
2.2. Macroscopic Assessment of Colitis. Mice were examined
daily, following treatment with DNBS, for signs of ill-
health and intestinal dysfunction: weight loss, fur ruﬄing,
decreased activity, and wet or bloody anal area or feces.
Upon autopsy, at 72hours post-DNBS, the colon was excised
and inspected for evidence of macroscopic damage. The
appearance and length of the colon was recorded to give
a Disease Activity Score based on the following criteria:
>10% loss of body weight (0 or 1); wet anus, soft stool, or
emptycolon(0-1);analbleeding(0or1);macroscopiculcers
present in the colon (0 or 1). If an animal deteriorated to
a predetermined morbidity endpoint (e.g., rectal prolapse,
obvious distress), it was humanely sacriﬁced and given a
score of 5 [7].
Subsequently, the colon was divided based on length
(contraction of the colon is characteristic of colitis in this
model [7]) and segments preserved for further testing. The
distal 20% was snap-frozen in liquid nitrogen for assay
of eosinophils peroxidase (EPO) activity, the adjacent 10%
segment was ﬁxed in 10% formalin for histological analysis
and the next 10% portion of colon was snap-frozen in liquid
nitrogen and stored for measurement of collagen levels (the
proximal colon was discarded).
2.3. Histological Assessment of Colitis. Formalin-ﬁxed,
paraﬃn-embedded segments of colon were sectioned
(3μm), collected on coded slides, stained with haematoxylin
and eosin and histological damage scored by an investigator
using the following criteria (max score = 12): loss of
architecture (0–3); inﬂammatory inﬁltrate (0–3); goblet
cell depletion (0-1); ulceration (0-1); edema (0-1); muscle
thickening (0–2); presence of crypt abscesses (0-1) [7].
Additional sections were stained with Mason’s trichrome
stain, which identiﬁes collagen as a blue reaction product.
2.4. Eosinophil Peroxidase Activity. Activity levels of EPO
were determined as previously described [16]. Brieﬂy the
presence of MPO was assessed using a kinetic assay where
H2O2 is broken down by the MPO released from the samples
of colon. This assay was repeated on duplicate sample
aliquots with the addition of 50mM 3-amino-1,2,4-triazole
(AMT; Sigma Chemical Co.) to inhibit EPO. EPO activity
was calculated by subtracting the MPO + AMT value from
MPO values.
2.5. Collagen Deposition. The amount of collagen in extracts
of colon was measured via the Sircol colometric assay
(Biocolor Ltd., N. Ireland, UK) following the manufactures
instructions.
2.6.Cytokine Production. Spleencellswere isolated following
ap r e v i o u s l yr e p o r t e dp r o t o c o l[ 7], and 5 ×106 cells (in 1mL
of RPMI medium) were activated with the T cell mitogen,
concanavalin A (ConA: at 2μg/mL). Culture media were
collected 48hours later and the levels of interleukin (IL)-10,
IL-4, interferon (IFN)-γ, or tumour necrosis factor (TNF)-
α were determined in duplicate serial dilutions using ELISA
protocols stipulated by the manufacture (R&D Systems)
[17]. ELISAs detection limits were 9pg/mL. The bioactivity
ofthedexamethasoneusedintheseexperimentswasassessed
by its ability to suppress IL-4, IFN-γ,a n dT N F - α production
by in vitro ConA-stimulated murine spleen cells.Journal of Biomedicine and Biotechnology 3
2.7. Peripheral Blood Immune Cells. Blood smears were
air dried and then stained using the Hema3 diﬀerential
staining kit following the manufactures instructions (Fisher
Scientiﬁc, Kalamazoo, MI). Mononuclear cells (T cells, B,
cells,monocytes),neutrophils,andeosinophilswerecounted
by a single investigator who was unaware of the treatment
groups.
2.8.StatisticalAnalysis. Dataarepresentedasthemean ±the
standard error of the mean (SEM), where n is the number
of mice (3–8/group) examined. Statistical comparisons were
by one way ANOVA followed by pairwise comparisons using
the Student’s t-test or Tukey’s test for nonparametric data. A
statistical diﬀerence was set at P< . 05.
3. Results
In preliminary experiments we conﬁrmed that the dexam-
ethasoneusedintheinvivoanalysiswasbioactive.Treatment
of spleen cells with ConA for 48hours resulted in the pro-
duction of 26 ± 2pg/mL of IL-4, 508 ± 104pg/mL of TNFα,
and 4412 ± 870pg/mL of IFNγ (n = 6): inclusion of DEX
(1μg/mL) completed blocked ConA-induced production of
these cytokines (levels of all 3 were undetectable in ELISA).
In two initial experiments, mice were treated with 3mg
DNBS ir; however, in these studies signiﬁcant morbidity was
observed with 66% (i.e., 6 of 9 (disease activity score = 4.6
± 0.2)), 12.5% (1 of 8 (disease activity score = 2.6 ± 0.4)),
and 25% (i.e., 2 of 8 (disease activity score = 3.8 ± 0.4)) of
mice treated with DNBS, H. diminuta +D N B Sa n dD N B S
+ DEX, respectively, reaching an endpoint that necessitated
sacriﬁce prior to completion of the experiment. Despite the
severity of the colitis, these data suggest that both infections
with H. diminuta and daily DEX treatments reduce the eﬀect
of DNBS. Subsequent experiments (described below) were
conducted with 2.5mg of DNBS.
3.1. Increased Eosinophils Conﬁrm Successful Infection with H.
diminuta. Diﬀerential staining of peripheral blood revealed
an increase in eosinophils (4.0 ± 0.6% (n = 3)) in blood
retrieved from H. diminuta + DNBS treated mice, conﬁrm-
ingsuccessfulinfectionwiththehelminth. Aneﬀectiveinfec-
tion was further substantiated by analysis of EPO activity
in tissue homogenates that revealed signiﬁcant increases in
tissues excised from H. diminuta- + DNBS treated mice (5.7
± 2.1 U/mg tissue) compared to control (2.1 ± 0.9), DNBS
(1.4 ± 0.7), and DNBS + DEX treated mice (0.8 ± 0.2) (n =
3), indicating that the mice had received a viable infection of
H. diminuta.
3.2. H. diminuta Is More Eﬀective than Daily DEX in Inhibit-
ing DNBS-Induced Colitis. As expected [7]m i c et r e a t e dwi t h
DNBS developed colitis as gauged by loss of body weight,
shortening of the colon and disease activity and histology
damage scores (Figure 1). Similarly, and corroborating our
earlier report, mice previously infected with H. diminuta
were protected against the procolitic eﬀects of intrarectal
DNBS treatment [7], and, in contrast, no anticolitic eﬀects
were observed in the DEX treated group, using the dose and
treatment regimen employed in these studies (Figures 1 and
2).
3.3. Infection with H. diminuta Induces IL-10 and IL-4
Production. Only spleen cells isolated from H. diminuta +
DNBS treated mice (n = 3) produced substantial amounts
of IL-10 (268 ± 122pg/mL) and IL-4 (437 ± 192pg/mL)
in response to a 48-hour treatment with ConA. Spleen cells
from control mice produced 0–24pg/mL of IL-10 and IL-4;
whereas neither cytokine was detected in culture medium
from spleen cells isolated from DNBS- or DNBS + DEX-
treated mice (n = 3–6). In contrast, lower amounts of IFNγ
and TNFα were found in conditioned medium from ConA-
stimulated spleen cells isolated from H. diminuta +D N B S
and DNBS + DEX-treated mice compared to DNBS only
treated mice (Figure 3). The latter shows that DEX was
having an in vivo eﬀect, despite the lack of inhibition of
colitis using the indices of gut form employed here.
3.4. Collagen Deposition Is Not Apparent in this Acute
Model of Colitis. Neither histochemical staining (Figure 2)
nor biochemical analysis (Figure 4) revealed any signiﬁcant
increases in collagen deposition in the colon in any of
the treatment groups (all examined 72hours post-DNBS)
compared to time-matched controls.
4. Discussion
Current medical management of many autoimmune and
inﬂammatory diseases, including IBD, relies heavily on the
use of steroids and broad-spectrum immunosuppressive
drugs [18]. While eﬀective in reducing disease symptoms,
both classes of therapeutic are associated with a range of
side eﬀects. In the case of steroids, these include moon-face,
ﬂuid retention, insomnia and weight gain, with more serious
eﬀects of long-term use being osteoporosis and suppression
of the hypothalamic-pituitary-adrenal axis. The use of
biologicals (e.g., anti-TNFα antibody) is increasing as these
drugs are proving very eﬀective in treating some patients
with aggressive disease that have failed other therapies [19];
however,theirusecomesatconsiderableﬁnancialcost.Thus,
in the ongoing search for additional therapeutics, a number
of investigators have revived an older notion that infection
with helminth parasites can ameliorate concomitant disease
[20]. The immunological basis of this postulate is that
the immune response mobilized by the host to combat
the parasitic helminth, whether it is TH2-immunity or
a generalized state of immuno-regulation/suppression, is
suﬃcient to antagonize or inhibit the immunopathological
events underlying, for example, atopic disease or IBD.
Substantial proof-of-concept data have accumulated
fromanalysesofrodentmodelsystemstoshowthatinfection
with helminth parasites either blocks the development of,
or signiﬁcantly reduces the severity of other diseases. With
respect to intestinal inﬂammation, infection with nematodes
(H. polygyrus, T. spiralis), trematodes (S. mansoni)a n d
cestodes (H. diminuta) can reduce colitis evoked by chemical4 Journal of Biomedicine and Biotechnology
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Figure 1: Bar graphs showing that infection with H. diminuta 8 days prior to DNBS (ir., 2.5mg), in contrast to 3 doses of dexamethosone
(DEX), reduces the severity of colitis as gauged by (a) body weight, (b) colon length, (c) disease activity scores, and (d) histological damage
scores (mean ± SEM; n = 6–8 mice from 2 experiments; ∗P<. 05 compared to control).
haptenizing agents, or that which spontaneously develops in
the IL-10 deﬁcient mouse (reviewed in [8]). The data from
these investigations have been complemented by preliminary
and provocative ﬁndings showing that “helminth therapy”
could be a viable option for the treatment of IBD and possi-
bly asthma [21]. The caveat here is that the introduction of a
species into a new niche can have unforeseen consequences,
and this needs to be borne in mind.
From the ability of infection with helminth parasites
to block inﬂammatory disease two questions arise: (1)
will immunological knowledge gleaned from the helminth-
rodent model systems translate into new treatments for
human disease? And, (2) are there side eﬀects of “helminth
therapy” (and by inference the application of immunological
knowledge from the helminth-rodent model systems)? In
relation to the former, analyses of infection with various
parasitic helminths have implicated IL-10, transforming
growth factor (TGF)-β,F o x P 3 + regulatory T cells, and the
inhibition of TH1 and TH17 events in the anti-colitic eﬀect
[4, 8, 22]. These cells and mediators have been implicated in
the pathogenesis/pathophysiology of human inﬂammatory
disease, conﬁrming the value of the helminth-rodent models
inthedevelopmentofputativetreatmentsforhumandisease.
The current study is, to our knowledge, the ﬁrst to
compare infection with parasitic helminths with another
therapeutic modality in a model of colitis: dexamethasone
(DEX) being selected as the comparator therapy. Consistent
withourearlierﬁndings[12],miceinfectedwithH.diminuta
were signiﬁcantly protected from the colitic eﬀect of ir.
instillation of DNBS. In contrast, and despite the DEX being
bioactive (it blocked ConA-induced cytokine production
from splenocytes in vitro), the severity of colitis-induced by
DNBS was unaﬀected by three consecutive daily doses of
DEX. This treatment regime (dose, route of administration,
repeated treatment) was based on studies in which DEX
blocked tri-nitrobenzene sulphonic acid- (TNBS-) induced
colitis [13–15, 23]. However, only a single study has shown
that DEX reduces DNBS-induced colitis in mice, and that
study used a tenfold higher dose of steroid than used here
[24]. Moreover, while our data are surprising, they are
not unprecedented. Atug et al. reported that a 7-day DEX
treatment did not alter TNBS-induced histopathology [25,
26] and others have shown that DEX inhibition of TNBS-
induced inﬂammation was not accompanied by reduced
local levels of IL-1β and actually increased colonic levels
of IFNγ [13]. Thus, while one can speculate on why DEX
was ineﬀective in blocking DNBS-colitis in the present study
(e.g., impact of microﬂora, suppression of a beneﬁcial anti-
colitic eﬀect), and despite the reduction in the production
in the synthesis of proinﬂammatory cytokines by spleen
cells (e.g., TNFα and IFNγ), the important comparison
remains that infection with H. diminuta was more eﬀec-
tive in blocking DNBS-colitis than a steroid treatment
regimen.Journal of Biomedicine and Biotechnology 5
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Figure 2: Representative images of gut morphology (hematoxylin and eosin (H&E stain); (a)) and collagen deposition ((b); collagen is
stained blue) in colonic sections from the 4 treatment groups (M: muscle; L: gut lumen; U: ulcer; arrow, inﬂammatory inﬁltrate: original
magniﬁcation = ×200).
Wehavepreviouslyexpressedtheconcernthat“helminth
therapy” would be of little value if it predisposed an indi-
vidual to hypersensitivity/asthmatic conditions or promoted
ﬁbrotic disease (both of which can occur in TH2 dominated
conditions) [16]. In the present study, we observed no
evidence, neither histochemical nor biochemical, in support
of additional deposition of collagen in the colon of mice
cotreated with H. diminuta + DNBS. Furthermore, using the
same experimental conditions, we found that the anticolitic
eﬀect of infection with H. diminuta was not associated with
increased sensitivity to bystander protein antigens [7]. Thus,
at least in this experimental paradigm with H. diminuta
in the nonpermissive mouse host and an acute model of
chemically induced colitis, signiﬁcant adverse eﬀects have
not been detected in association with the anticolitic eﬀect.
However, this does not preclude the possibility of long-term
side eﬀects, and studies to address this need to be conducted
in this and other model systems.
Inconclusion,signiﬁcantmomentumhasbeengenerated
in the last few years in the assessment of the ability of infec-
tion with helminth parasites to block concomitant disease
[8, 21]. These studies have the potential to identify one or
more“therapeutichelminths”(thecaveatsofpalatabilityand
iatrogenic infection notwithstanding) and, perhaps more
pertinently, can identify novel immunological molecules or
signaling pathways that can serve as the basis of targets for
new therapeutics. As this research area advances, we need to
compare and contrast “helminth therapy” with other treat-
ments and exhaustively assess potential side eﬀects. In this
context, we found that H. diminuta was more eﬀective than6 Journal of Biomedicine and Biotechnology
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Figure 4: Bar graph showing the amount of collagen deposition in
the colon of control, DNBS (ir, 2.5mg) and H. diminuta-infected (5
cysticercoids, 8 days prior to DNBS) + DNBS treated mice (mean ±
SEM; n = 3).
the steroid dexamethasone in preventing DNBS-induced
colitis and that the beneﬁt of infection with the helminth was
not accompanied by increased deposition of collagen in the
colon.
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